Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap1.92B
Enterprise Value1.90B
CUE
(NASDAQ)Cue Biopharma, Inc.
$20.43-- (--)
Loading... - Market loading
Cue Biopharma (CUE) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)70.02
Forward Price/Sales23.34
Price/Book (mrq)72.75
Price/Tangible Book (mrq)72.75
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue69.18
EV/Earnings-71.43
EV/EBITDA-77.97
EV/EBIT-71.99
EV/FCF-86.91
Stock Price
Current price, 52-week range, and moving averages
Current Price$20.43
1-Day Change0.64%
52-Week High$41.42
52-Week Low$0.23
52-Week Change4070.44%
YTD Change5955.13%
1-Year Change3298.20%
50-Day MA$14.61
200-Day MA$5.24
Avg Volume (30 day)1.36M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding94.73M
Book Value per Share$0.28
Net Cash per Share$0.24
FCF per Share$-0.23
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin88.33%
EBITDA Margin (ttm)-88.73%
EBIT Margin (ttm)-96.09%
Operating Margin (ttm)-96.56%
Pretax Margin (ttm)-95.03%
Profit Margin (ttm)-96.85%
FCF Margin (ttm)-79.60%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-100.64%
Return on Assets (ttm)-63.02%
Return on Invested Capital (ttm)-596.92%
Return on Capital Employed (ttm)-91.90%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue27.47M
Gross Profit24.26M
Operating Income-26.52M
Pretax Income-26.10M
Net Income-26.60M
EBITDA-24.37M
EBIT-26.39M
Diluted EPS$-8.38
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-21.69M
Capital Expenditures177.00K
Free Cash Flow-21.86M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth200.31%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)42.21M
Cash & Securities (mrq)27.14M
Net Cash (mrq)22.94M
Net Cash per Share$0.24
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)4.20M
Working Capital (mrq)23.49M
Total Equity (mrq)26.43M
Book Value per Share$0.28
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.74
Quick Ratio (mrq)2.74
Debt/Equity (mrq)0.16
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-1.38%
FCF Yield-1.14%
Buyback Yield-1.60%
Total Shareholder Yield-1.60%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score60.15
Piotroski F-Score4/9
Frequently Asked Questions About Cue Biopharma Statistics
What are the key financial metrics for CUE?
Cue Biopharma, Inc. (CUE) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is CUE's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Cue Biopharma is overvalued or undervalued.
How do I read CUE's profitability ratios?
Cue Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do CUE's debt ratios indicate?
The financial health section shows Cue Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is CUE's dividend analysis?
The dividend section covers Cue Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.